<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10724">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02967354</url>
  </required_header>
  <id_info>
    <org_study_id>Dnr 2012/302</org_study_id>
    <nct_id>NCT02967354</nct_id>
  </id_info>
  <brief_title>[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes</brief_title>
  <official_title>[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per-Ola Carlsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cross-sectional study to investigate subjects at different stages of type 2 diabetes
      development with expected stratification of pancreatic islet mass. Non-diabetic individuals
      were assigned as control. The primary outcome was the [11C]5-hydroxy-tryptophan uptake and
      retention in the pancreas as a surrogate marker for the endogenous islet mass.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>[11C]5-hydroxy-tryptophan uptake in the pancreas</measure>
    <time_frame>Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release</time_frame>
    <description>Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pancreatic perfusion</measure>
    <time_frame>Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release</time_frame>
    <description>Uptake of radioactive water with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic volume</measure>
    <time_frame>Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreatic fat content</measure>
    <time_frame>Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic fat content</measure>
    <time_frame>Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with oral antidiabetic drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI&gt;30, Type 2 diabetes treated with oral antidiabetic drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese, treated with oral antidiabetic drugs + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI&gt;30, Type 2 diabetes treated with oral antidiabetic drugs + insulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal weight, treated with oral antidiabetic drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal weight, treated with oral antidiabetic drugs + insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan</intervention_name>
    <description>Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan</description>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Obese with oral antidiabetic drugs</arm_group_label>
    <arm_group_label>Obese, treated with oral antidiabetic drugs + insulin</arm_group_label>
    <arm_group_label>Normal weight, treated with oral antidiabetic drugs</arm_group_label>
    <arm_group_label>Normal weight, treated with oral antidiabetic drugs + insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes fulfilling criteria for the four different study groups, or healthy
             volunteers

        Exclusion Criteria:

          -  Ongoing pregnancy

          -  Renal failure (GFR&lt;60 ml/min)

          -  Magnetic metal parts in the body

          -  Ongoing treatment with selective serotonin receptor inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 15, 2016</lastchanged_date>
  <firstreceived_date>November 8, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Per-Ola Carlsson</investigator_full_name>
    <investigator_title>Professor, Senior consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>5-Hydroxytryptophan</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
